Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIME: Intranasal Dexmedetomidine for Myocardial Injury in PCI
NCT07847580Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Randomised trial in coronary artery disease (CAD) comparing Intranasal DEX group with Placebo group (2 arms). Primary endpoint: Incidence of periprocedural myocardial injury at 48 hours. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
dexmedetomidine
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT07847580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07847580.